Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBLAZE: Encorafenib + Binimetinib in BRAF-mutated Thyroid Cancer (Real-world, Multi-center Study)
jRCT1031260160Recruiting
- Sponsor
- National Cancer Center Hospital East
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of encorafenib and binimetinib in thyroid cancer and anaplastic thyroid cancer (ATC), sponsored by National Cancer Center Hospital East. Primary endpoints: Treatment status at initiation and during encorafenib + binimetinib therapy, Investigator-assessed overall response rate (ORR) per RECIST v1.1 and 1 more. Started May 2026; status: recruiting.
02
Drugs
encorafenibbinimetinib
03
Conditions
thyroid canceranaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on jRCT1031260160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031260160.